Emrusolmin

DB13927InvestigationalSmall molecule

Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.

Mechanism: There is evidence that anle138b blocks the activity of conducting Aβ pores without changing the membrane embedded Aβ-oligomer structure.
Curator reviewed · 1 reference
Formula / weight: C₁₆H₁₁BrN₂O₂ · 343.18 g/mol (avg)
Also known as: 1H-PYRAZOLE, 3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)- · 3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)-1H-PYRAZOLE
Code names: ANLE-138b · CS-6522 · HY-101855 · TEV-56286

Resolves to

Compound

UNIIE7WRA77JETCAS882697-00-9ChEMBLCHEMBL4748063

Structure

InChIKeyRCQIIBJSUWYYFU-UHFFFAOYSA-NSMILESBrC1=CC=CC(=C1)C1=NNC(=C1)C1=CC2=C(OCO2)C=C1

Targets

P37840SNCA

What you can answer from here — as of May 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Emrusolmin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account